Diagnosing Drug-Resistant Tuberculosis with the Xpert®MTB/RIF. The Risk for Rifampin Susceptible Cases
Open Access
- 1 January 2017
- journal article
- research article
- Published by Scientific Research Publishing, Inc. in Journal of Tuberculosis Research
- Vol. 05 (03), 155-160
- https://doi.org/10.4236/jtr.2017.53017
Abstract
Setting: Tuberculosis clinic in México. Objective: Since the Xpert®MTB/RIF does not detect resistance to isoniazid, our objective was to emphasize the need for additional drug susceptibility testing. Design: A prospective study. All patients with an Xpert®MTB/RIF and a positive tuberculosis culture with drug susceptibility testing were included. Results: 70 patients were included. Forty-two (60%) had a history of previous treatment for TB. Fourteen patients (20%) had a strain resistant to isoniazid (H), twelve of them (85.7%) with a history of TB treatment in the past vs. 2 (7.1%) among new cases (p = 0.028). Four patients (5.7%) had resistance to rifampin (R); three of them were previously treated cases. Additionally, six patients with a negative Xpert test (8.6%) had a positive MGIT culture; three of them were resistant to H (the 3 were poly-resistant). Two patients with a positive Xpert®MTB/RIF test without R resistance were phenotypically multidrug-resistant. Conclusion: Isoniazid resistance is associated with overall increased treatment failure, relapse, and acquired multidrug resistance in patients treated with regimens containing only first-line tuberculosis drugs. It is urgent that national TB programs implement the necessary infrastructure to complement the Xpert®MTB/RIF results with DST either by phenotypic or genotypic methods.Keywords
This publication has 11 references indexed in Scilit:
- Xpert MTB/RIF for rapid detection of rifampicin-resistant Mycobacterium tuberculosis from pulmonary tuberculosis patients in Southwest EthiopiaInternational Journal of Mycobacteriology, 2016
- Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2016
- Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?European Respiratory Journal, 2016
- Xpert® MTB/RIF detection of rifampin resistance and time to treatment initiation in Harare, ZimbabweThe International Journal of Tuberculosis and Lung Disease, 2016
- Primary drug resistance in a region with high burden of tuberculosis. A critical problem.Salud Publica de Mexico, 2015
- Correlation between Genotypic and Phenotypic Testing for Resistance to Rifampin in Mycobacterium tuberculosis Clinical Isolates in Haiti: Investigation of Cases with Discrepant Susceptibility ResultsPLOS ONE, 2014
- Do We Need to Detect Isoniazid Resistance in Addition to Rifampicin Resistance in Diagnostic Tests for Tuberculosis?PLOS ONE, 2014
- Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistanceFuture Microbiology, 2011
- Quantifying the Burden and Trends of Isoniazid Resistant Tuberculosis, 1994–2009PLOS ONE, 2011
- Standardized Treatment of Active Tuberculosis in Patients with Previous Treatment and/or with Mono-resistance to Isoniazid: A Systematic Review and Meta-analysisPLoS Medicine, 2009